Biomedical or Dental Material
GSK Invests $546M in Rgenta’s RNA Modulation Technology for Cancer and Other Diseases
GSK, Rgenta, RNA modulation, cancer treatment, pharmaceutical investment
Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million
Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal
Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros
Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal
Novartis Invests $1 Billion in PTC’s Huntington’s Disease Program
Novartis, PTC, Huntington’s disease, pharmaceutical investment, gene therapy
Kyowa Kirin Invests $330M in Kura’s Leukemia Drug, Gaining Shared Rights Ahead of FDA Submission
Kyowa Kirin, Kura, leukemia drug, FDA submission, pharmaceutical investment
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D
ALK-Abell Acquires Epinephrine Nasal Spray for $145 Million
ALK-Abell, Epinephrine Nasal Spray, Acquisition, Pharmaceutical Portfolio
Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast
Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales
Bayer and Dewpoint Therapeutics Collaborate on Dilated Cardiomyopathy Program with $424 Million Deal
Bayer, Dewpoint Therapeutics, Dilated Cardiomyopathy, DCM, Pharmaceutical Deal
Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development
Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment